Jan 19, 2015

Farmak adds Metakos pharmaceutical drug to its oncology portfolio

Farmak, a leader of the domestic pharmaceutical industry, continues extending the oncology line of pharmaceutical products. Thus, Metakos, a new drug, is added to the Company’s portfolio.

This medicinal product is produced in the form of concentrate for solution for infusion (vial, 5 ml, No 1). Metakos contains zoledronic acid as active agent.

The medicinal product is prescribed for:

It is worth to remind that Farmak’s portfolio of pharmaceutical drugs for treatment of oncological diseases includes such products as Letromara (letrozole as active agent), Androfarm (cyproterone as active agent) and Flutafarm (flutamide as active agent).

Back to the News

Our website uses cookies to ensure proper site functionality, analyse traffic, improve service quality, and deliver personalized marketing and advertising. To learn more, please view the Cookie Policy at link. By clicking “Accept All”, you consent to the use of all cookie categories
Accept All
Reject All